Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Cytokinetics, Incorporated (CYTK)

Core Viewpoint - A securities class action lawsuit has been filed against Cytokinetics, alleging false and misleading statements regarding the New Drug Application for aficamten and its approval timeline [1][2]. Group 1: Lawsuit Details - The lawsuit is filed in the United States District Court for the Northern District of California on behalf of individuals or entities that acquired Cytokinetics securities between December 27, 2023, and May 6, 2025 [1]. - The complaint claims that Cytokinetics misrepresented the expected approval timeline from the FDA for aficamten, indicating a PDUFA date of September 26, 2025, while failing to disclose risks related to the submission of a Risk Evaluation and Mitigation Strategy [2]. Group 2: Investor Information - Investors who purchased Cytokinetics shares are encouraged to contact the law firm before the lead plaintiff motion deadline on November 17, 2025 [3]. - The lead plaintiff will represent the interests of other class members in the litigation process [3].